May 26, 2011

The company behind Enfamil baby formula has introduced a new mobile application for expecting mothers.

May 20, 2011

The Food and Drug Administration has approved a new antiretroviral treatment for HIV made by Johnson & Johnson, the agency said Friday.

April 5, 2011

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

March 25, 2011

The Food and Drug Administration has approved a new treatment for late-stage skin cancer, the agency said Friday.

March 24, 2011

Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

March 8, 2011

The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.

March 7, 2011

Drug maker Bristol-Myers Squibb is opening a new testing facility in China under collaboration with a local company there, Bristol said Monday.

February 23, 2011

The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

February 18, 2011

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 17, 2011

The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.

February 14, 2011

An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.

January 7, 2011

A new oral treatment for Type 2 diabetes hit the shelves Friday.

December 21, 2010

Bristol-Myers Squibb has signed a definitive licensing pact with Oncolys BioPharma, a privately held Japanese biotech company, that will give it control of a promising new HIV treatment.

December 8, 2010

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

December 7, 2010

The Food and Drug Administration has accepted for review a supplemental approval application for an arthritis drug made by Bristol-Myers Squibb, the drug maker said Monday.

November 15, 2010

The U.S. District Court for the District of Delaware has upheld a patent held by...

November 14, 2010

Look for a big surge in brand-to-generic drug switches at the pharmacy counter over the...

November 10, 2010

A drug maker's philanthropic arm announced its commitment to fight Type 2 diabetes in the...

November 7, 2010

The Food and Drug Administration approved the first and only once-a-day metformin extended-release plus dipeptidyl...

November 7, 2010

Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a...

October 27, 2010

The Food and Drug Administration has approved a new usage for a blood cancer drug,...

October 4, 2010

The Food and Drug Administration has approved a generic drug for HIV made by a...

September 27, 2010

The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired,...

September 23, 2010

An investigational diabetes drug works as well as a generic already on the market, according...